18F-FDG PET scanning correlates with tissue markers of poor prognosis and predicts mortality for patients after liver resection for colorectal metastases

Journal of Nuclear Medicine

Volumn 48, Issue 5, 2007, Pages 771-775

  Riedl, Christopher C ^a   Akhurst, Timothy ^a   Larson, Steven ^a   Stanziale, Stephen F ^a   Tuorto, Scott ^a   Bhargava, Amit ^a   Hricak, Hedvig ^a   Klimstra, David ^a   Fong, Yuman ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

18F FDG; Hepatic metastases; Outcome; PET; Prognostic variables; SUV

Indexed keywords

FLUORODEOXYGLUCOSE F 18; GLUCOSE TRANSPORTER 1; GLUCOSE TRANSPORTER 3; KI 67 ANTIGEN; PROTEIN BCL 2; PROTEIN P27; PROTEIN P53; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER MORTALITY; CANCER SURVIVAL; COLORECTAL CANCER; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER METASTASIS; LIVER RESECTION; MAJOR CLINICAL STUDY; MALE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; BLOOD; CLINICAL TRIAL; COLORECTAL TUMOR; INCIDENCE; LIVER TUMOR; METASTASIS; METHODOLOGY; MIDDLE AGED; MORTALITY; REPRODUCIBILITY; RISK ASSESSMENT; RISK FACTOR; SCINTISCANNING; SENSITIVITY AND SPECIFICITY; STATISTICS; SURVIVAL RATE; TREATMENT OUTCOME; UNITED STATES;

ADULT; AGED; AGED, 80 AND OVER; COLORECTAL NEOPLASMS; FEMALE; FLUORODEOXYGLUCOSE F18; HEPATECTOMY; HUMANS; INCIDENCE; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEW YORK; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT; RISK FACTORS; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 34250625327     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.106.037291     Document Type: Article

References (24)

1. Fernandez FG, Drebin JA, Linehan DC, Dehdashti F, Siegel BA, Strasberg SM. Five-year survival after resection of hepatic metastases from colorectal cancer in patients screened by positron emission tomography with F-18 fluorodeoxyglucose (FDG-PET). Ann Surg. 2004;240:438-447.
2. Akhurst T, Larson SM. Positron emission tomography imaging of colorectal cancer. Semin Oncol. 1999;26:577-583.
3. Flamen P, Lerut A, Van CE, et al. Utility of positron emission tomography for the staging of patients with potentially operable esophageal carcinoma. J Clin Oncol. 2000;18:3202-3210.
4. 18F] fluorodeoxyglucose positron emission tomography on surgical management of melanoma patients. Br J Surg. 2006;93:243-249.
5. Johnson GR, Zhuang H, Khan J, Chiang SB, Alavi A. Roles of positron emission tomography with fluorine-18-deoxyglucose in the detection of local recurrent and distant metastatic sarcoma. Clin Nucl Med. 2003;28:815-820.
6. Pieterman RM, van Putten JW, Meuzelaar JJ, et al. Preoperative staging of non-small-cell lung cancer with positron-emission tomography. N Engl J Med. 2000;343:254-261.
7. 18F-FDG PET preoperative staging of colorectal cancer: comparison with conventional staging and its impact on treatment decision making. J Nucl Med. 2003;44:1784-1788.
8. Hong D, Lunagomez S, Kim EE, et al. Value of baseline positron emission tomography for predicting overall survival in patient with nonmetastatic esophageal or gastroesophageal junction carcinoma. Cancer. 2005;104:1620-1626.
9. 18F] Fluorodeoxyglucose uptake by positron emission tomography predicts outcome of non-small-cell lung cancer. J Clin Oncol. 2005;23:1136-1143.
10. 18F-FDG PET in staging and early prediction of response to therapy of recurrent gastrointestinal stromal tumors. J Nucl Med. 2004;45:17-21.
11. Ramos CD, Erdi YE, Gonen M, et al. FDG-PET standardized uptake values in normal anatomical structures using iterative reconstruction segmented attenuation correction and filtered back-projection. Eur J Nucl Med. 2001;28:155-164.
12. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
13. Breese JS, Heckerman D, Kadie C. Empirical analysis of predictive algorithms for collaborative filtering. In: Proceedings of the 14th Annual Conference on Uncertainty in Artificial Intelligence (UAI-98). San Francisco, CA: Morgan Kaufman; 1998:43-52.
14. Lardinois D, Weder W, Hany TF, et al. Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography. N Engl J Med. 2003;348:2500-2507.
15. Strasberg SM, Dehdashti F, Siegel BA, Drebin JA, Linehan D. Survival of patients evaluated by FDG-PET before hepatic resection for metastatic colorectal carcinoma: a prospective database study. Ann Surg. 2001;233:293-299.
16. Downey RJ, Akhurst T, Gonen M, et al. Preoperative F-18 fluorodeoxyglucose-positron emission tomography maximal standardized uptake value predicts survival after lung cancer resection. J Clin Oncol. 2004;22:3255-3260.
17. Higashi K, Ueda Y, Ayabe K, et al. FDG PET in the evaluation of the aggressiveness of pulmonary adenocarcinoma: correlation with histopathological features. Nucl Med Commun. 2000;21:707-714.
18. 11C] acetate in normal prostate and benign prostatic hyperplasia: comparison with prostate cancer. Eur J Nucl Med Mol Imaging. 2002;29:1492-1495.
19. 18F]-FLT) as positron emission tomography tracer for imaging proliferation in a murine B-cell lymphoma model and in the human disease. Cancer Res. 2003;63:2681-2687.
20. Akhurst T, Fong Y. Positron emission tomography in surgical oncology. Adv Surg. 2002;36:309-331.
21. Banerjee D, Gorlick R, Liefshitz A, et al. Levels of E2F-1 expression are higher in lung metastasis of colon cancer as compared with hepatic metastasis and correlate with levels of thymidylate synthase. Cancer Res. 2000;60:2365-2367.
22. Kawamura T, Kusakabe T, Sugino T, et al. Expression of glucose transporter-1 in human gastric carcinoma: association with tumor aggressiveness, metastasis, and patient survival. Cancer. 2001;92:634-641.
23. Folpe AL, Lyles RH, Sprouse JT, Conrad EU III, Eary JF. (F-18) Fluorodeoxyglucose positron emission tomography as a predictor of pathologic grade and other prognostic variables in bone and soft tissue sarcoma. Clin Cancer Res. 2000;6:1279-1287.
24. Koukourakis MI, Giatromanolaki A, Harris AL, Sivridis E. Comparison ofmetabolic pathways between cancer cells and stromal cells in colorectal carcinomas: a metabolic survival role for tumor-associated stroma. Cancer Res. 2006;66:632-637.